Literature DB >> 18997738

Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization.

Sanjay Kakar1, Xin Chen, Coral Ho, Lawrence J Burgart, Vaibhav Sahai, Somkid Dachrut, Annoel Yabes, Dhanpat Jain, Linda D Ferrell.   

Abstract

Fibrolamellar hepatocellular carcinoma is a rare subtype of hepatocellular carcinoma with distinct clinical and histological features, and better survival compared with conventional hepatocellular carcinoma in some but not all series. We performed a comparative genomic hybridization analysis on 11 fibrolamellar carcinomas and correlated the findings with clinicopathologic features and survival. Chromosomal imbalances were identified in six cases (55%), whereas the other five (45%) yielded normal results. The mean number of aberrations per case was 3.9 for all cases and 7.2 in abnormal cases. Among the six abnormal cases, gains or losses were observed at 3 loci in two cases, 7 loci in one case, 8 loci in two cases and 14 loci in one case. The most common abnormalities were observed in chromosomes 7, 8 and 18, with 7q gain in five cases and 7p gain in four cases. Aberrations associated with intermediate or advanced conventional hepatocellular carcinomas, including losses at 3q, 4q and 13q were identified in 17-33% of fibrolamellar carcinomas. There was no correlation of chromosomal changes with age, gender and tumor size. The 5-year survival among the six patients with no chromosomal abnormalities was 80% (4/5) compared with 33% (2/6) in patients with chromosomal abnormalities (P=0.1). In conclusion, fibrolamellar carcinomas show fewer chromosomal abnormalities compared with those reported in literature for conventional hepatocellular carcinoma. The most common abnormalities occur in chromosomes 7 and 8. Fibrolamellar carcinomas with chromosomal changes appear to behave more aggressively compared with cases with no cytogenetic abnormalities. The favorable outcome in some fibrolamellar carcinomas may be due to absent or low number of cytogenetic aberrations.

Entities:  

Mesh:

Year:  2008        PMID: 18997738     DOI: 10.1038/modpathol.2008.178

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

1.  Genomic analysis of fibrolamellar hepatocellular carcinoma.

Authors:  Lei Xu; Florette K Hazard; Anne-Flore Zmoos; Nadine Jahchan; Hassan Chaib; Phillip M Garfin; Arun Rangaswami; Michael P Snyder; Julien Sage
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

2.  Molecular characteristics of fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Péter Törzsök; Ilona Kovalszky; Tamás Barbai; Erzsébet Rásó; Gábor Lotz; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2012-08-08       Impact factor: 3.201

3.  Cell cycle biology of fibrolamellar hepatocellular carcinoma.

Authors:  Sadhna Dhingra; Wei Li; Dongfeng Tan; Maryam Zenali; Haizeng Zhang; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-11-02

4.  Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Beate K Straub; Peter Schirmacher; Ilona Kovalszky; Gábor Lotz; András Kiss; Zsuzsa Schaff
Journal:  Virchows Arch       Date:  2011-04-19       Impact factor: 4.064

5.  Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver.

Authors:  Wolfgang Tränkenschuh; Florian Puls; Matthias Christgen; Cord Albat; Albert Heim; Jeanette Poczkaj; Peer Fleming; Hans Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

6.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

Review 7.  Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.

Authors:  Gadi Lalazar; Sanford M Simon
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

8.  The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients.

Authors:  David G Darcy; Rachel Chiaroni-Clarke; Jennifer M Murphy; Joshua N Honeyman; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Oncotarget       Date:  2015-01-20

9.  A genomic case study of mixed fibrolamellar hepatocellular carcinoma.

Authors:  O L Griffith; M Griffith; K Krysiak; V Magrini; A Ramu; Z L Skidmore; J Kunisaki; R Austin; S McGrath; J Zhang; R Demeter; T Graves; J M Eldred; J Walker; D E Larson; C A Maher; Y Lin; W Chapman; A Mahadevan; R Miksad; I Nasser; D W Hanto; E R Mardis
Journal:  Ann Oncol       Date:  2016-03-30       Impact factor: 32.976

Review 10.  Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.

Authors:  Kevin M Riggle; Rigney Turnham; John D Scott; Raymond S Yeung; Kimberly J Riehle
Journal:  Pediatr Blood Cancer       Date:  2016-03-14       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.